

HR 7188

Shandra Eisenga Human Cell and Tissue Product Safety Act

Congress: 118 (2023–2025, Ended)

Chamber: House

Policy Area: Health

Introduced: Feb 1, 2024

Current Status: Received in the Senate.

Latest Action: Received in the Senate. (Dec 17, 2024)

Official Text: <https://www.congress.gov/bill/118th-congress/house-bill/7188>

Sponsor

Name: Rep. Moolenaar, John R. [R-MI-2]

Party: Republican • State: MI • Chamber: House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Dingell, Debbie [D-MI-6]	D · MI		Feb 1, 2024

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Reported by	May 16, 2024

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Shandra Eisenga Human Cell and Tissue Product Safety Act

This bill requires federal agencies to update guidance, regulations, and educational materials about transplants involving human cell and tissue products, particularly with respect to safety and eligibility standards.

Specifically, the Department of Health and Human Services must support the development of educational materials for health care providers about issues relating to organ, tissue, and eye donations; screening tests; and other aspects of donations. The Food and Drug Administration (FDA) must review current guidance on donor eligibility and, if appropriate, update it with information on how to reduce the spread of tuberculosis or sepsis in association with donations. The FDA must also publish information about its Tissue Reference Group and data about FDA inspections and registrations of human cell and tissue establishments.

The bill also establishes specific civil penalties for violations of regulations governing procedures for human cell and tissue products. The FDA must consider and recommend ways to update these regulations after a public comment period.

Actions Timeline

- **Dec 17, 2024:** Received in the Senate.
- **Dec 16, 2024:** Mr. Bucshon moved to suspend the rules and pass the bill, as amended.
- **Dec 16, 2024:** Considered under suspension of the rules. (consideration: CR H7167-7170)
- **Dec 16, 2024:** DEBATE - The House proceeded with forty minutes of debate on H.R. 7188.
- **Dec 16, 2024:** Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)
- **Dec 16, 2024:** On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)
- **Dec 16, 2024:** Motion to reconsider laid on the table Agreed to without objection.
- **Nov 22, 2024:** Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-766.
- **Nov 22, 2024:** Placed on the Union Calendar, Calendar No. 632.
- **Sep 18, 2024:** Committee Consideration and Mark-up Session Held
- **Sep 18, 2024:** Ordered to be Reported (Amended) by the Yeas and Nays: 40 - 0.
- **May 16, 2024:** Subcommittee Consideration and Mark-up Session Held
- **May 16, 2024:** Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 27 - 0.
- **Feb 2, 2024:** Referred to the Subcommittee on Health.
- **Feb 1, 2024:** Introduced in House
- **Feb 1, 2024:** Referred to the House Committee on Energy and Commerce.